Davidson Matt reported AZR

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0001213900-26-115985

Machine-readable

Structured copy

Timestamps

Event (reported)

Nov 2, 2026

Published

Nov 4, 2026

Ingested by INSIDER

Nov 4, 22:39 UTC

Last re-read

Nov 4, 23:10 UTC

Extracted facts

Filer

Davidson Matt

Role

Director, President and CEO

Transaction

Derivative conversionAs filed: “C”

Asset

Azora Therapeutics, Inc. (DE) — Series A Preferred Stock

Ticker

AZR

Shares

101.3

Price per share

$0

Execution date (reported)

Nov 2, 2026

Owned after transaction

0 shares

Days from execution to publication

2

What this establishes

Davidson Matt filed this Form 4 reporting a derivative conversion of AZR on Nov 2, 2026. It became public on Nov 4, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director, President and CEO

Davidson Mattcik:0001741937

Issuer

Azora Therapeutics, Inc. (DE)cik:0001513525

Revision history · 0

No field has changed since this record was first ingested.